Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:1
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [21] Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
    Mayr, Roman
    Burger, Maximilian
    CURRENT UROLOGY REPORTS, 2013, 14 (02) : 90 - 93
  • [22] Current Concepts in the Management of Non-Muscle Invasive Bladder Cancer
    Mandhani A.
    Indian Journal of Surgical Oncology, 2017, 8 (3) : 397 - 402
  • [23] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    De Berardinis, E.
    Busetto, G. M.
    Antonini, G.
    Giovannone, R.
    Gentile, V.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2011, 43 (04) : 1047 - 1057
  • [24] Alternatives for cytology in the management of non-muscle invasive bladder cancer
    Amiel G.E.
    Shu T.
    Lerner S.P.
    Current Treatment Options in Oncology, 2004, 5 (5) : 377 - 389
  • [25] Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
    Pak, Sahyun
    Kim, Sun-Young
    Kim, Sung Han
    Joung, Jae Young
    Park, Weon Seo
    Chung, Jinsoo
    Lee, Kang Hyun
    Seo, Ho Kyung
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
    François Audenet
    Adam M. Farkas
    Harry Anastos
    Matthew D. Galsky
    Nina Bhardwaj
    John P. Sfakianos
    World Journal of Urology, 2018, 36 : 1741 - 1748
  • [27] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
    Audenet, Francois
    Farkas, Adam M.
    Anastos, Harry
    Galsky, Matthew D.
    Bhardwaj, Nina
    Sfakianos, John P.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (11) : 1741 - 1748
  • [28] A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer
    de Jong, Joep J.
    de Jong, Florus C.
    van der Made, Angelique C. J.
    van Casteren, Niels J.
    Roshani, Hossain
    Oomens, Eric H. G. M.
    Pelger, Rob C. M.
    Steyerberg, Ewout W.
    Boormans, Joost L.
    Bangma, Chris H.
    Zuiverloon, Tahlita C. M.
    Zwarthoff, Ellen C.
    BLADDER CANCER, 2024, 10 (03) : 233 - 242
  • [29] Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer
    Wiesen, Brett
    Hargis, Paige
    Flores, Hunter
    Kukreja, Janet
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [30] Immune Therapies in Non-Muscle Invasive Bladder Cancer
    Philip L. Ho
    Stephen B. Williams
    Ashish M. Kamat
    Current Treatment Options in Oncology, 2015, 16